ENPP2 and cancer: In silico analysis of publicly available genomic data at The Cancer Genome Atlas (11) indicated genetic alterations, mostly amplifications, of ENPP2 in cancer patients, with the highest rates observed in ovarian (33%), breast (20%), liver (20%), and lung (11%) carcinomas (12).